Combined therapy for thyroid squamous cell carcinoma

• Published in: Head & neck Vol. 34; no. 1; pp. 131 - 134
• Main Authors: De Vos, Filip Yves F. L., Sewnaik, Aniel, de Wilt, J. Hans W., Smid, Ernst J., den Bakker, Michael A., van Meerten, Esther, Rosenthal, Eben L.
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.01.2012; Wiley
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; carcinoma; Carcinoma, Squamous Cell - drug therapy; Carcinoma, Squamous Cell - surgery; cell; Cisplatin - administration & dosage; Combined Modality Therapy; Dermatology; Endocrinopathies; Female; Humans; Induction Chemotherapy; Malignant tumors; Medical sciences; Middle Aged; Otorhinolaryngology. Stomatology; Paclitaxel - administration & dosage; radiochemotherapy; squamous; thyroid; Thyroid Neoplasms - drug therapy; Thyroid Neoplasms - surgery; Thyroid. Thyroid axis (diseases); Tumors of the skin and soft tissue. Premalignant lesions; Endocrinopathy; Skin disease; Squamous cell carcinoma; Basal cell carcinoma; Stomatology; Thyroid diseases; ENT; Thyroid gland; Malignant tumor; Thyroid carcinoma; squamous; radiochemotherapy; thyroid; carcinoma; Combined treatment; Cell; Cancer
• ISSN: 1043-3074; 1097-0347
• DOI: 10.1002/hed.21484

Background. Squamous carcinoma of the thyroid is a rare aggressive disease, resulting in poor prognosis. Methods and Results. We combined cisplatin with paclitaxel on a weekly basis as induction therapy, achieving a high cumulative dose, in a patient with squamous cell tumor of the thyroid with arterial encasement. After surgery, pathologic examination confirmed a complete resection of the primary tumor with clear margins, revealing a successful induction treatment with chemotherapy. Conclusions. Our patient now has a recurrence‐free survival of >20 months, longer than the mean survival described in the literature. © 2010 Wiley Periodicals, Inc. Head Neck, 2012